Evidence map›Paper›PMID 36579243›Full record

ReviewCureus2022

Use of Ivermectin and Chlorine Dioxide for COVID-19 Treatment and Prophylaxis in Peru: A Narrative Review.

Angie de Los Milagros Farfán-Castillo, Rosangela Simone Moreno-Núñez, Fátima Milagros Zárate-Yuyes, Lissett Jeanette Fernández-Rodríguez, Victor Hugo Bardales-Zuta

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Angie de Los Milagros Farfán-CastilloSchool of Human Medicine, Antenor Orrego Private University, Trujillo, PER.
Rosangela Simone Moreno-NúñezSchool of Human Medicine, Antenor Orrego Private University, Trujillo, PER.
Fátima Milagros Zárate-YuyesSchool of Human Medicine, Antenor Orrego Private University, Trujillo, PER.
Lissett Jeanette Fernández-RodríguezSchool of Human Medicine, Antenor Orrego Private University, Trujillo, PER.
Victor Hugo Bardales-ZutaSchool of Human Medicine, Antenor Orrego Private University, Trujillo, PER.
Antenor Orrego Private University · PE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, created a rapidly unfolding health crisis, especially in the initial phases of the pandemic. In the early stages of the pandemic, various strategies were proposed for COVID-19 prophylaxis and treatment with very little scientific evidence available. Among these proposed treatments were ivermectin and chlorine dioxide, which were both used widely in Peru for both disease prevention and treatment without considering their problematic side effects. For instance, ivermectin was part of an approved therapeutic scheme based on in vitro data, although its efficacy in humans was not demonstrated. In addition, chlorine dioxide was never shown to be effective but causes threatening side effects. In this article, we discuss current information regarding chlorine dioxide and ivermectin in the context of the COVID-19 pandemic, with a focus on experiences in Peru.

Indexed as

alternative medicinechlorine dioxidecovid-19ivermectinperu

Identifiers

PMID36579243
PMCPMC9788901
OpenAlexW4309818170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.